Amundi Bei Gene, Ltd. Transaction History

Amundi

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$129.52 - $174.32 $165,008 - $222,083	1,274 Added 430.41%	1,570 $223,000
Q1 2024 May 15, 2024	BUY	$141.8 - $181.47 $19,426 - $24,861	137 Added 86.16%	296 $46,000
Q4 2023 Feb 14, 2024	SELL	$158.67 - $201.58 $5,553 - $7,055	-35 Reduced 18.04%	159 $28,000
Q3 2023 Nov 14, 2023	BUY	$179.87 - $225.13 $13,130 - $16,434	73 Added 60.33%	194 $34,000
Q2 2023 Aug 14, 2023	SELL	$178.3 - $266.78 $120,887 - $180,876	-678 Reduced 84.86%	121 $21,000
Q1 2023 May 15, 2023	SELL	$215.53 - $274.5 $11.6 Million - $14.8 Million	-54,030 Reduced 98.54%	799 $172,000
Q4 2022 Feb 14, 2023	SELL	$125.51 - $229.3 $4.97 Million - $9.08 Million	-39,610 Reduced 41.94%	54,829 $12.1 Million
Q3 2022 Nov 14, 2022	BUY	$131.8 - $202.24 $890,968 - $1.37 Million	6,760 Added 7.71%	94,439 $13.6 Million
Q2 2022 Aug 15, 2022	SELL	$121.11 - $216.05 $352,430 - $628,705	-2,910 Reduced 3.21%	87,679 $15.4 Million
Q1 2022 May 16, 2022	BUY	$146.52 - $269.56 $208,058 - $382,775	1,420 Added 1.59%	90,589 $19.3 Million
Q4 2021 Feb 14, 2022	SELL	$248.56 - $389.34 $1.41 Million - $2.2 Million	-5,662 Reduced 5.97%	89,169 $21.1 Million
Q3 2021 Nov 15, 2021	BUY	$249.6 - $403.14 $311,750 - $503,521	1,249 Added 1.33%	94,831 $34.4 Million
Q2 2021 Aug 16, 2021	BUY	$292.75 - $367.01 $27.4 Million - $34.3 Million	93,582 New	93,582 $32.1 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.6B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Amundi, based on Form 13F filings with the SEC.

Stay updated on Amundi with notifications on news.